|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
|
| |
| __NOTOC__ | | __NOTOC__ |
| {{Cellulitis}} | | {{Cellulitis}} |
|
| |
|
| ==Overview==
| | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. |
| | |
| ==Future Therapies==
| |
| | |
| {| style="border: 0px; font-size: 85%; margin: 3px;" align=center
| |
| |+
| |
| ! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|}}
| |
| ! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Chloroquine}}
| |
| ! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Ribavirin}}
| |
| ! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|6-Azauridine}}
| |
| ! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Arbidol}}
| |
| ! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Harringtonine}} | |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC;" | Assay type
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells)
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Human
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells)
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero and primary human fibroblast cells)
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |In vitro (BHK21 cells)
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC;" | Hypothesized target
| |
| | style="padding: 5px 5px; background: #F5F5F5;" | Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification.
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Can interact with the intracellular viral RNA production.
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine.
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process.
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins.
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC;" | Advantages
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC;" | Disadvantages
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC;" | References
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #FFF;" colspan="6"| <SMALL>Table adapted from </SMALL>
| |
| |-
| |
| |}
| |
|
| |
|
| ==References== | | ==References== |
| Line 59: |
Line 8: |
|
| |
|
| [[Category:Disease]] | | [[Category:Disease]] |
| [[Category:Infectious disease]]
| | |
| [[Category:Dermatology]] | | [[Category:Dermatology]] |
| [[Category:Emergency medicine]] | | [[Category:Emergency medicine]] |